Bank of New York Mellon Corp Invests $15.38 Million in Prestige Consumer Healthcare Inc. $PBH

Key Points

• Bank of New York Mellon acquired 325,275 shares of Prestige Consumer Healthcare worth approximately $15.38 million, representing about 0.69% of the company. Institutional investors collectively own 99.95% of PBH.
• Prestige Consumer Healthcare exceeded quarterly expectations, reporting $0.98 EPS versus the $0.89 consensus and revenue of $265.71 million, up 6.5% year over year. Management issued fiscal 2027 EPS guidance of $4.55–$4.65.
• Analyst sentiment remains mixed, with an overall “Hold” rating and a consensus price target of $70.75 versus the stock’s reported price of $51.81. Ratings included two Buys, three Holds, and one Sell.

Bank of New York Mellon Corp acquired a new stake in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 325,275 shares of the company's stock, valued at approximately $15,376,000. Bank of New York Mellon Corp owned approximately 0.69% of Prestige Consumer Healthcare at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. UMB Bank n.a. lifted its position in Prestige Consumer Healthcare by 110.1% in the fourth quarter. UMB Bank n.a. now owns 418 shares of the company's stock worth $26,000 after purchasing an additional 219 shares during the period. Versant Capital Management Inc increased its position in shares of Prestige Consumer Healthcare by 47.9% during the 2nd quarter. Versant Capital Management Inc now owns 726 shares of the company's stock valued at $34,000 after purchasing an additional 235 shares during the period. Caitong International Asset Management Co. Ltd increased its position in shares of Prestige Consumer Healthcare by 69.8% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 574 shares of the company's stock valued at $35,000 after purchasing an additional 236 shares during the period. Danske Bank A S bought a new stake in shares of Prestige Consumer Healthcare in the 3rd quarter worth $37,000. Finally, Cornerstone Planning Group LLC bought a new stake in shares of Prestige Consumer Healthcare in the 1st quarter worth $44,000. Institutional investors and hedge funds own 99.95% of the company's stock.

Prestige Consumer Healthcare Price Performance

Shares of NYSE:PBH opened at $51.81 on Tuesday. Prestige Consumer Healthcare Inc. has a one year low of $42.62 and a one year high of $71.07. The stock has a fifty day moving average of $50.35 and a 200-day moving average of $54.44. The company has a market capitalization of $2.45 billion, a PE ratio of 14.51, a price-to-earnings-growth ratio of 1.64 and a beta of 0.34. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.99 and a current ratio of 3.23.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported $0.98 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.89 by $0.09. The business had revenue of $265.71 million for the quarter, compared to analysts' expectations of $253.02 million. Prestige Consumer Healthcare had a return on equity of 11.39% and a net margin of 15.57%.The company's quarterly revenue was up 6.5% on a year-over-year basis. During the same period in the previous year, the firm posted $0.90 EPS. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS. As a group, equities analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.56 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

PBH has been the subject of several research reports. Zacks Research raised Prestige Consumer Healthcare from a "strong sell" rating to a "hold" rating in a research note on Monday, August 10th. Oppenheimer cut shares of Prestige Consumer Healthcare from an "outperform" rating to a "market perform" rating in a research report on Thursday, May 14th. Weiss Ratings downgraded shares of Prestige Consumer Healthcare from a "hold (c-)" rating to a "sell (d+)" rating in a report on Thursday, June 25th. Finally, Canaccord Genuity Group reduced their price objective on shares of Prestige Consumer Healthcare from $86.00 to $72.00 and set a "buy" rating for the company in a research report on Friday, May 15th. Two investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $70.75.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women's health.

Key brands in Prestige's portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women's health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).

Want to see what other hedge funds are holding PBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source